Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with
selected advanced solid tumors and to identify the minimum safe and biologically
effective/recommended dose (RD) and schedule for XmAb808.